{
    "clinical_study": {
        "@rank": "13383", 
        "arm_group": [
            {
                "arm_group_label": "Male volunteers", 
                "arm_group_type": "Experimental", 
                "description": "Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants."
            }, 
            {
                "arm_group_label": "Female volunteers", 
                "arm_group_type": "Experimental", 
                "description": "Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants."
            }
        ], 
        "brief_summary": {
            "textblock": "This non-treatment study will investigate the effects on mood and performance caused by\n      hallucinogens and other psychoactive compounds."
        }, 
        "brief_title": "Effects of Hallucinogens and Other Drugs on Mood and Performance", 
        "completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Twenty volunteers between 21-50 years old will each participate in 16 total sessions,\n      including sessions for: screening, preparation, experiment/drug, immediate follow-ups, a\n      1-month follow-up and 1 post completion urine collection. On each of five experimental\n      session participants will orally ingest capsules of either a placebo or varying doses of one\n      of 18 different psychoactive compounds.\n\n      Subjective drug effects will be examined with methods previously used by this laboratory for\n      characterizing the effects of psychoactive substances from a variety different classes.\n      Volunteers will swallow capsules containing various doses of drugs, complete tasks during\n      the session, and rate effects of the drug and complete questionnaires at the end of each\n      session as described below."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be 21 to 50 years old\n\n          -  Have given written informed consent\n\n          -  Have a high school level of education\n\n          -  Agree to consume approximately the same amount of caffeine-containing beverage (e.g.,\n             coffee, tea) that he/she consumes on a usual morning, before arriving at the research\n             unit on the mornings of drug session days. If the volunteer does not usually consume\n             caffeinated beverages, he or she must agree not to do so on session days\n\n          -  Cigarette smokers must agree to abstain from smoking on session days from 1 hour\n             before drug administration until at least 6 hours after drug administration\n\n          -  Agree to refrain from using any psychoactive drugs, including alcoholic beverages,\n             within 24 hours of each drug administration. Exceptions include daily use of caffeine\n             and nicotine.\n\n          -  Be healthy and psychologically stable as determined by screening for medical problems\n             via a personal interview, a medical questionnaire, a physical examination, an\n             electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests\n\n          -  Agree that for one week before each session, he/she will refrain from taking any\n             nonprescription medication, nutritional supplement, or herbal supplement except when\n             approved by the study investigators. Exceptions will be evaluated by the study\n             investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs,\n             and common doses of vitamins and minerals\n\n          -  Agree not to take any PRN prescription medications on the mornings of the sessions\n\n          -  Be willing and able to participate\n\n        Exclusion criteria:\n\n          -  Women who are pregnant (as indicated by a positive urine pregnancy test assessed at\n             intake and before each drug session) or nursing; women who are of child-bearing\n             potential and sexually active who are not practicing an effective means of birth\n             control\n\n          -  Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled\n             hypertension, a clinically significant ECG abnormality (e.g., atrial fibrillation),\n             or TIA in the past year\n\n          -  Epilepsy with history of seizures\n\n          -  Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of\n             hypoglycemia\n\n          -  Currently taking psychoactive prescription medication on a regular (e.g., daily)\n             basis\n\n          -  Currently taking on a regular (e.g., daily) basis any medications having a primary\n             centrally-acting pharmacological effect on serotonin neurons or medications that are\n             MAO inhibitors. For individuals who have intermittent or PRN use of such medications,\n             sessions will not be conducted until at least 5 half-lives of the agent have elapsed\n             after the last dose\n\n          -  More than 20% outside the upper or lower range of ideal body weight\n\n        Psychiatric Exclusion Criteria:\n\n          -  Current or past history of meeting DSM-IV criteria for schizophrenia, psychotic\n             disorder (unless substance-induced or due to a medical condition), or bipolar I or II\n             disorder\n\n          -  Current severe obsessive-compulsive disorder, dysthymic disorder, or panic disorder.\n\n          -  Current, severe, major depression\n\n          -  Have a first or second degree relative with schizophrenia, psychotic disorder (unless\n             substance induced or due to a medical condition), or bipolar I or II disorder\n\n          -  Currently meets DSM-IV criteria for dissociative disorder, anorexia nervosa, bulimia\n             nervosa, or other psychiatric conditions judged to be incompatible with establishment\n             of rapport or safe exposure to DXM and psilocybin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033707", 
            "org_study_id": "NA_00082804"
        }, 
        "intervention": {
            "arm_group_label": [
                "Male volunteers", 
                "Female volunteers"
            ], 
            "description": "One of the following or placebo will be given:\nHallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis\nSedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem\nAntihistamines: diphenhydramine, chlorpheniramine\nStimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion\nOpioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine\nOther: alcohol, scopolamine, nicotine\nEach volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are \"blind\" to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.", 
            "intervention_name": "Hallucinogens and psychoactive substances", 
            "intervention_type": "Drug", 
            "other_name": [
                "Hallucinogens", 
                "Sedatives & anxiolytics", 
                "Antihistamines", 
                "Stimulants", 
                "Opioids", 
                "Alcohol", 
                "Scopolamine", 
                "Nicotine"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Central Nervous System Stimulants", 
                "Histamine Antagonists", 
                "Histamine H1 Antagonists", 
                "Scopolamine", 
                "Butylscopolammonium Bromide", 
                "Nicotine", 
                "Hallucinogens", 
                "Hypnotics and Sedatives", 
                "Anti-Anxiety Agents", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hallucinogen", 
            "Cognitive effects", 
            "Subjective effects"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "contact": {
                "email": "tcarbon4@jhu.edu", 
                "last_name": "Theresa Carbonaro, Ph.D.", 
                "phone": "410-550-2983"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21224"
                }, 
                "name": "Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center"
            }, 
            "investigator": {
                "last_name": "Roland R Griffiths, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I Study Characterizing Effects of Hallucinogens and Other Drugs on Mood and Performance", 
        "overall_contact": {
            "email": "ehurwit2@jhmi.edu", 
            "last_name": "Ethan Hurwitz", 
            "phone": "410-550-3074"
        }, 
        "overall_contact_backup": {
            "email": "tcarbon4@jhu.edu", 
            "last_name": "Theresa Carbonaro, Ph.D.", 
            "phone": "410-550-2983"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Roland R Griffiths, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Volunteer-completed questionnaire assesses the subjective liking of the drug condition for the session", 
            "measure": "Rating of \"Drug Liking\" on the End of Day Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "Completed at the end of the experimental session (approximately 8 hours after capsule administration)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033707"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Roland Griffiths", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "This questionnaire has been used in various studies to characterize the profile of subjective and cognitive effects of various types of drugs classified as hallucinogens", 
            "measure": "Hallucinogen Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "Completed at the end of the experimental session (approximately 8 hours after capsule administration)"
        }, 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}